Formosa Pharmaceuticals announced on March 17 that its novel ophthalmic drug, APP13007, has been granted market authorization by Health Canada. The drug is indicated for the treatment of inflammation and pain following cataract surgery.

• Strategic Partnership: The product will be commercialized by Apotex Inc. under an exclusive licensing agreement signed in August 2024. Formosa Pharmaceuticals will serve as the primary manufacturer and supplier.
• Market Opportunity: According to Apotex, Canada performs approximately 500,000 ophthalmic surgeries annually. The market for steroid-based eye drops is valued at US$36 million and is growing at a steady 5% CAGR.

Resource: 台新藥APP13007獲加拿大核准上市 攻白內障術後炎症與疼痛治療市場